Methods of treating breast cancer with anthracycline therapy
AssigneesThe University of North Carolina at Chapel Hill, Washington University, University of Utah Research Foundation, British Columbia Cancer Agency Branch
InventorsCharles M. Perou, Matthew J. Ellis, Philip S. Bernard, Torsten O. Nielsen
Life of this patent
Estimating the term…
Abstract
The application describes methods for screening subjects with breast cancer to determine if the breast cancer will be responsive to a breast cancer therapy including an anthracycline. The application also describes methods for treating subjects with breast cancer by screening them for the likelihood of the effectiveness of treating the cancer with a therapy including anthracycline and administering the therapy in subjects when it is found that anthracycline is likely to be effective.
Claims12
A method of treating breast cancer in a subject in need thereof comprising:
- (a) providing a biological sample from the subject;
- (b) assaying the biological sample to determine whether the biological sample is classified as a Her2+ subtype;
- (c) assaying the biological sample to determine whether the biological sample is classified as a Her-2-E subtype;
- (d) providing an assessment of the likelihood of effectiveness of a breast cancer treatment comprising an anthracycline in the subject, wherein if the biological sample is classified as both a Her2+ subtype and a Her-2-E subtype, the breast cancer treatment comprising the anthracycline is more likely to be effective in the subject and wherein if the biological sample is classified as a Her-2-E subtype and is classified as not a Her2+ subtype, the breast cancer treatment comprising the anthracycline is less likely to be effective in the subject;
- and
- (e) administering a breast cancer treatment comprising anthracycline to the subject subsequent to said assessment if the biological sample is classified as both a Her2+ subtype and a Her-2-E subtype and administering a breast cancer treatment not comprising anthracycline to the subject subsequent to said assessment if the biological sample is classified as a Her-2-E subtype and classified as not a Her2+ subtype, thereby treating breast cancer in the subject.
Dependencies are inferred from the claim text.